Skip to main content
. 2013 Sep 9;4(9):1527–1546. doi: 10.18632/oncotarget.1291

Figure 1. Combination NK+mAb9.2.27 treatment ablates tumor growth, prolongs survival and presented a tropism for cytotoxic cells in combination treated in U87MG bearing rats.

Figure 1

(A) Longitudinal axial post-contrast T1-weighted images of nude rats bearing U87MG tumors treated with combination NK+mAb9.2.27, NK cell monotherapy, mAb9.2.27 monotherapy, and untreated controls, showing the same animal after 4, 5 weeks and 3 months post NK+mAb9.2.27 treatment. (B), (C) Plot showing the quantification of (B) tumor proliferation by % Ki67 labeling index and (C) cell death by % area fraction TUNEL positive apoptotic/necrotic cells. Data represent mean ± SEM of all tumors in the groups. ***p<0.001 and **p<0.01. (D) Kaplan –Meier survival curves showing surviving fraction, n=7 animals/group. (E) H&E staining of U87MG tumor with necrosis (scale bar 200μm, magnification 100X). Increased myeloperoxidase positive cells in mAb9.2.27 and combination treated tumors compared to control and NK treated tumors (scale bar 100μm, magnification 200X). High granzyme B positivity in combination treated tumors (scale bar 100μm, magnification 400X). Quantification of (F) MPO and (G) granzyme B positive cells. Data in (F) and (G) represent mean SEM from all tumors in the groups. *p<0.05, **p<0.001.